

# Emily P Zeitler, Mhs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716792/publications.pdf>

Version: 2024-02-01

44  
papers

719  
citations

471509

17  
h-index

552781

26  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1220  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter. <i>Europace</i> , 2022, 24, 1754-1762.	1.7	3
2	Comparative effectiveness of cardiac resynchronization therapy in older patients with heart failure: Systematic review and meta-analysis. <i>Journal of Cardiac Failure</i> , 2022, 28, 443-452.	1.7	3
3	Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 147-157.	4.1	1
4	Leadless pacemaker implantation complications and the denominator problem. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 160-163.	1.7	1
5	Women in procedural leadership roles in cardiology: The Women In Local Leadership (WILL) observational study. <i>Heart Rhythm</i> , 2022, 19, 623-629.	0.7	5
6	Arrhythmias in Female Patients: Incidence, Presentation and Management. <i>Circulation Research</i> , 2022, 130, 474-495.	4.5	17
7	Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 172-174.	4.1	0
8	Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 763-771.	1.4	4
9	Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1050-1059.	2.8	9
10	Evaluation of cardiovascular implantable electronic device leads post implant: ElectroPhysiology Predictable And Sustainable Implementation Of National Registries (EP PASSION). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, , 1.	1.3	4
11	Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy. <i>Circulation</i> , 2021, 143, 661-672.	1.6	47
12	Pre-Diabetes and Stroke in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 885-887.	2.8	1
13	Funding of Studies Supporting IA Guideline Recommendations in Cardiovascular Medicine—A Systematic Review. <i>Journal of the American Heart Association</i> , 2021, 10, e019513.	3.7	2
14	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. <i>JAMA Cardiology</i> , 2021, 6, 1275.	6.1	49
15	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDR ICD Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1897-1906.	1.2	3
16	Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. <i>Heart Rhythm</i> , 2020, 17, 447-454.	0.7	20
17	Regulation Without Representation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008561.	4.8	1
18	Defibrillator Lead Survival. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006649.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Novel Devices in Heart Failure. JACC: Heart Failure, 2020, 8, 251-264.	4.1	11
20	A difficult entanglement: Guidewire entrapment within the submitral apparatus following transseptal access. HeartRhythm Case Reports, 2020, 6, 819-822.	0.4	0
21	Fidelis Replacement. JACC: Clinical Electrophysiology, 2019, 5, 1068-1070.	3.2	0
22	Physicians' perceptions of shared decision-making for implantable cardioverter-defibrillators: Results of a physician survey. Journal of Cardiovascular Electrophysiology, 2019, 30, 2420-2426.	1.7	8
23	Arrhythmia care in a value-based environment: Past, present, and future. Heart Rhythm, 2018, 15, e5-e15.	0.7	8
24	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. Europace, 2018, 20, 1621-1629.	1.7	20
25	Risk of atrioesophageal fistula formation with contact force-sensing catheters. Heart Rhythm, 2017, 14, 1328-1333.	0.7	91
26	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2017, 69, 2369-2379.	2.8	37
27	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	2.7	29
28	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. American Heart Journal, 2017, 191, 21-29.	2.7	35
29	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. Circulation, 2017, 136, 1387-1395.	1.6	58
30	Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. Journal of Cardiovascular Electrophysiology, 2017, 28, 1345-1351.	1.7	18
31	Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women." Circulation: Heart Failure, 2016, 9, .	3.9	0
32	Remote monitoring of cardiac implantable electronic devices (CIED). Trends in Cardiovascular Medicine, 2016, 26, 568-577.	4.9	35
33	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	25
34	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	3.9	28
35	Predictable and Sustainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). American Heart Journal, 2016, 171, 64-72.e2.	2.7	7
36	Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. Heart Rhythm, 2015, 12, 1233-1240.	0.7	35

#	ARTICLE	IF	CITATIONS
37	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. <i>Clinical Trials</i> , 2015, 12, 511-519.	1.6	20
38	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	4.1	30
39	Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. <i>Heart Rhythm</i> , 2015, 12, 1558-1564.	0.7	12
40	A Company of Equals. <i>Journal of the American College of Cardiology</i> , 2015, 66, 589-591.	2.8	1
41	Primary prevention implantable cardioverter defibrillators in women: More questions than answers. <i>American Heart Journal</i> , 2015, 170, 197-199.	2.7	0
42	Exercise Training and Pacing Status in Patients With Heart Failure: Results From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2015, 21, 60-67.	1.7	32
43	Abstract 9920: Outcomes Associated With Lead Abandonment versus Lead Extraction Strategies for Revision of Sterile Leads: An NCDRA® Analysis. <i>Circulation</i> , 2015, 132, .	1.6	0
44	The J wave patterns and risk of sudden cardiac death in patients with coronary artery disease. <i>Journal of Electrocardiology</i> , 2013, 46, 446-450.	0.9	0